@article{oai:nagasaki-u.repo.nii.ac.jp:00010316,
 author = {Ichinose, Kunihiro and Origuchi, Tomoki and Kawashiri, Shin-ya and Iwamoto, Naoki and Fujikawa, Keita and Aramaki, Toshiyuki and Kamachi, Makoto and Arima, Kazuhiko and Tamai, Mami and Nakamura, Hideki and Ida, Hiroaki and Kawakami, Atsushi and Eguchi, Katsumi},
 issue = {2},
 journal = {Rheumatology International},
 month = {Feb},
 note = {We present six cases of patients with Japanese rheumatoid arthritis (RA) treated with a tumor necrosis factor (TNF)-alpha blocking agent, adalimumab as monotherapy for 220 weeks. All six patients were women, and the median age was 54.0 ± 7.07 years old. The median duration of the disease was 7.43 ± 11.1 years, and the median disease activity score (DAS28-CRP) was 5.35 ± 0.69. Three of six patients were able to continue to receive this treatment for 220 weeks successfully, and the DAS28-CRP decreased to 1.89 ± 0.75. Two patients withdrew because of lack of efficacy, and one patient withdrew because of adverse events (non-Hodgkin lymphoma). Adalimumab resulted in a sustained clinical response in RA patients during 220-week follow-up., Rheumatology International, 32(2), 483-187; 2012},
 pages = {483--487},
 title = {Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases},
 volume = {32},
 year = {2012}
}